Infantile Spasm (West Syndrome) and Companies Involved in Therapeutics Development

Infantile Spasm (West Syndrome) and Companies Involved in Therapeutics Development
Ethocle Reports latest Pharmaceutical and Healthcare disease pipeline guide Infantile Spasm (West Syndrome) – Pipeline Review, H2 2016, provides an overview of the Infantile Spasm (West Syndrome) (Central Nervous System) pipeline landscape. Infantile spasms are a type of epilepsy with a characteristic age of onset (typical age when seizures start), pattern of seizures and electroencephalogram (EEG). Symptoms include typical pattern is of a sudden flexion (bending forward) in a tonic (stiffening) fashion of the body, arms and legs. Sometimes, the episodes are different, with the arms and legs being flung outwards (these are called ‘extensor’ spasms). Causes include central nervous system infections, abnormal brain development or injury, genetic abnormalities (Down syndrome, Miller-Dieker syndrome) and metabolic disorders (mitochondrial diseases, phenylketonuria, and hypoglycemia). Treatment includes antiepileptic medications.
Report Highlights Ethocle Reports Pharmaceutical and Healthcare latest pipeline guide Infantile Spasm (West Syndrome) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Read Complete Report @ http://www.ethoclereports.com/report_details/5858fd30821fb12b5484a9da
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 4 respectively.Infantile Spasm (West Syndrome). Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The guide is built using data and information sourced from Ethocle Reports proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Infantile Spasm (West Syndrome) (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System). –
Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Infantile Spasm (West Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics. –
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Buy this report@ http://www.ethoclereports.com/report_details/5858fd30821fb12b5484a9da
Table of Content includes:-
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Infantile Spasm (West Syndrome) Overview 6
Therapeutics Development 7
Pipeline Products for Infantile Spasm (West Syndrome) - Overview 7
Infantile Spasm (West Syndrome) - Therapeutics under Development by Companies 8
Infantile Spasm (West Syndrome) - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Infantile Spasm (West Syndrome) - Products under Development by Companies 11
Infantile Spasm (West Syndrome) - Companies Involved in Therapeutics Development 12
Anavex Life Sciences Corp 12
Catalyst Pharmaceuticals Inc 13
GW Pharmaceuticals Plc 14
INSYS Therapeutics Inc 15
Novartis AG 16
Retrophin Inc 17
Infantile Spasm (West Syndrome) - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ANAVEX-273 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
AVL-5189 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
cannabidiol - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
cannabidiol - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
cosyntropin - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
cosyntropin ER - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
CPP-115 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
JBPOS-0101 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Infantile Spasm (West Syndrome) - Dormant Projects 52
Infantile Spasm (West Syndrome) - Product Development Milestones 53
Featured News & Press Releases 53
Sep 19, 2016: Catalyst Pharmaceuticals Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports 53
Jun 22, 2016: Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms 53
Jun 21, 2016: GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS) 54
May 18, 2016: Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms 54
Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD 55
Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115 55
Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms 56
Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115 56
Sep 02, 2014: Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115 57
Nov 18, 2013: Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia 58
Feb 13, 2012: Catalyst Receives Orphan Medicinal Product Designation In EU For CPP-115 To Treat West Syndrome 58
Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference 59
Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry 60
Dec 13, 2011: Catalyst Starts Phase Ia Safety Study For CPP-115 60
Dec 02, 2011: Catalyst To Present Data On CPP-115 At American Epilepsy Society's 65th Annual Meeting 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

Syndrome) – Pipeline Review, H2 2016, provides an overview of the Infantile Spasm (West Syndrome) (Central Ethocle Reports latest Pharmaceutical and Healthcare disease pipeline guide Infantile Spasm (West Nervous System) pipeline landscape.

Ethocle Reports
Rex Villa, Sr. No-36, Mozeswadi, Vadgaonsheri. Pune-411014

+91 20 6533 3231

+1 302 261 5322

info@ethoclereports.com

This release was published on openPR.